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(vPDT) fell from 93% to 68%. In the ‘without ranibizumab’ scenario, only vPDT was 
administered. Costs of treatment, administration, monitoring, bilateral disease and 
management of recurrences were included. Results: An estimated 2045 patients 
were eligible for treatment at year 1 and 2119 at year 5. In the ‘with ranibizumab’ 
scenario, 143 patients received ranibizumab at year 1, increasing to 678 at year 5; 
1902 patients received vPDT at year 1 and 1441 at year 5. ‘With ranibizumab’ annual 
costs were higher in years 1–2 than ‘without ranibizumab’ costs. During years 3, 
4 and 5, cost savings occurred with ranibizumab (£3867, £121 584 and £232 467, 
respectively), owing to lower total costs of treatment and monitoring than with 
vPDT. The total 5-year saving ‘with ranibizumab’ over ‘without ranibizumab’ was 
£227 086. ConClusions: Treating visual impairment due to CNV secondary to PM 
with ranibizumab rather than vPDT is estimated to provide significant cost savings 
in England and Wales over 5 years.
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Diabetic retinopathy (DR) is one of the main reasons of vision loss. Traditional 
treatment provides insufficient control of disease and adverse events. New drug 
ranibizumab usage in treatment of DR opens new opportunities in treatment of DR. 
objeCtives: To provide pharmacoeconomic assessment of ranibizumab in DR treat-
ment in the Russian Federation. Methods: Comparative modeling cost-effective-
ness (CEA) and budget impact (BIA) analyses based on clinical trials results were 
conducted. CEA with 1 year time horizon for basic group patients and BIA with 
5 year time horizon for high risk vision loss patient group. CEA considered only 
direct costs (DC), while BIA dealt with both DC and indirect costs (IC). 1 EURO = 40 
RUB. Results: Annual total costs (TC) per patient (PP) for ranibizumab treatment (8 
injections on the average) approached 9786 EURO. Annual TC for LC treatment were 
440 EURO PP. Ranibizumab provides 6,1 letters vision improvement on the average, 
while LC – 0,8 letters. Cost-effectiveness ratio (CER) for ranibizumab was 1604 EURO 
per letter, for LC CER was 550 EURO per letter. ICER was 1764 EURO per additional 
letter. Second scenario included DR patients going blind in 5 years on LC treatment, 
while on ranibizumab treatment they could keep their eyesight. TC over 5 years for 
ranibizumab treatment (13 injections on the average) were 15225 EURO PP. TC over 
5 years on LC were 27327 EURO PP, including IC due to vision loss – 25250 EURO. BIA 
results have shown that ranibizumab treatment for high-risk vision loss DR patients 
group provided 9 616 EURO (discounted at 3,5%) cost-saving PP in comparison with 
LC treatment. ConClusions: Ranibizumab is highly effective costly treatment 
that demands additional consideration for administration in common DR patient 
group, while it seems to be cost-saving in DR patient group of high-risk vision loss.
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objeCtives: To evaluate the impact of Herpes Zoster (HZ) as associated diagnosis 
on hospitalizations for an other main health problem, using 3 evaluation crite-
ria: length of stay, number of death and cost from the national health insurance 
perspective. Methods: The hospitalizations of people aged 50 years and more 
were selected from the French national hospital database (PMSI) 2011 using ICD 
10 diagnosis code: HZ (B02*) in associated diagnosis (DAS), and excluding codes of 
immunosuppressive conditions (D8* or B20*-B24*). The 5 main categories of diseases 
leading to hospitalization distribution allowed us to select, in decreasing order of 
importance: circulatory (I0*-I5* & I7*-I9*), respiratory (J0*-J9*), digestive (K0*-K9*), 
osteo-articular systems (M0*-M9*), and diabetes (E1*). For each of the 5 categories, a 
retrospective case-control has been realized. The cases are defined by hospitaliza-
tions with HZ in DAS and controls were hospitalizations without HZ in DAS matched 
on age and sex to the cases. Statistical non parametric analyses (Wilcoxon-Mann-
Whitney) in each of the five categories have been realized to evaluate the difference 
in length of stay, death rate, and cost. Results: In each of the five categories, cases 
presented a statistically significant length of stay compared to the controls. Median 
differences varying of 3 days for osteo-articular system (+50%) to 6 days for diges-
tive system (+300%). None difference in the death rates has been observed. The 
study also demonstrated a statistically significant cost of cases compared to the 
controls median differences varying of 857€ for circulatory system (+25%), 922€ for 
osteo-articular system (+26%), 945€ for respiratory system (+26%), 987€ for diabetes 
(+39%), and 2011€ for digestive system (+126%). ConClusions: When present as 
an associated diagnosis in hospitalizations of people 50+ for other medical reasons, 
HZ significantly increases the length of stay at hospital and subsequent economic 
burden for the French health system.
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objeCtives: The aim of this study was to compare spectacle independence and 
vision-related quality of life following implantation of a multifocal intraocular 
lens (IOL: ReSTOR®) or monofocal IOLs. Methods: This prospective observational 
study involved 206 cataract surgery patients (median age 71 years, range 51–90 
years) receiving either the multifocal IOL or monofocal IOLs. The primary outcome 
measures were the proportion of patients with a postoperative improvement in 
uncorrected visual acuity of 0.1 logMAR or better, the proportion of patients achiev-
ing spectacle independence, and vision-related quality of life assessed using the 
was in line with current data. Pulmonary symptoms call for vigilance in monitoring 
children. Chronic ocular inflammation sometimes is the cause of long-term cata-
racts in patients with atopic disorders. Early ocular symptoms found in this cohort 
must be specified and suggest that an opthamological follow-up may be required 
in some cases. In addition, the abnormally high consumption of antiseptics - and 
also often the source of irritation - raises concerns about children’s treatment.
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objeCtives: Actinic keratoses (AK) are dermatological conditions with the risk-
potential becoming squamous cell carcinoma (SCC). Descriptions of AK-epidemiology 
and cost-of-illness are currently necessary when submitting an AMNOG dossier for an 
AK-product in Germany. Methods: To describe AK-epidemiology a targeted litera-
ture research was conducted in PubMed in 2012, using the search terms (epidemiology 
OR incidence OR prevalence). To find relevant cost-of-illness information the following 
search terms were used (cost OR costs OR burden OR econom* OR pharmacoeconom* 
OR financ* OR budget OR reimburs* OR (resource NEAR (use OR utilization))). Both 
searches were combined with AND ((actinic OR solar OR senil*) AND (keratos* OR 
cheilitis)) AND Germany. PubMed research was supplemented by additional searches 
in guidelines and the World Wide Web for publications in German/English. Results: 
The screening of the epidemiology results (36 in PubMed) identified two relevant 
publications of four studies investigating AK-prevalence in Germany (Schäfer epub 
ahead of print 2012, Lichte 2010). An additional search for the German phrase “nicht 
melanozytäre Hautkarzinome” identified a publication on the cost-benefit of skin-
cancer-screening, including data on prevalence of AK (Guther 2011). The study results 
demonstrate a prevalence range between 2.0% and 7.4% with increasing prevalence 
by age. So far no cost-of-illness data of AK were identified for Germany (5 hits in 
pubmed). In an expert survey from Augustin and Kornek (2012) one important cost-
factor was seen in the progression of AK into SCC and its prevention might reduce 
treatment cost and burden of disease for patients. Citation tracking of this expert-
survey identified an additional prevalence-study in Germany (prevalence 2%, Augustin 
2011). ConClusions: No data of AK-incidence in Germany are available. Prevalence 
data of AK in Germany have a broad range from 2.0% - 7.4%. Cost-of-illness data are 
needed for Germany to demonstrate the cost saving aspect of AK-prevention as seen 
in cost-of-illness studies of other countries.
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objeCtives: In Europe only few and inconsistent data on the prevalence and 
treatment of Actinic Keratoses (AK) are available. Objective of this study was to 
determine the prevalence of AK in Germany, to identify potential predictors and to 
estimate the number of AK cases treated in dermatologic practices. Methods: In a 
multiple-source-approach, prevalence was assessed from whole-body-examinations 
in a cohort of 90.800 employees and from nationwide statutory health insurance 
(SHI) data of 2008. c) The number of cases documented in dermatological offices was 
estimated from statistics of a SHI Physicians Association. Results: Standardized 
prevalence of AK from dermatological examinations was 2.7%; the rate increased 
with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for 
women (1.5%). Significant associations were also identified for skin phototype I, 
sunburns in childhood and solar lentigines. Vitiligo and a history of melanoma were 
also but not significantly associated with AK. In the SHI data analysis standardized 
AK prevalence was 1.8%. Age-specific rates were below 1.5% up to 60 years and rose 
to 8.2% (13.2% in men) in the group 80-89 years. The prevalence from these large 
data sets - which is at the lower limit of studies from other countries – suggests 
about 1.7 Mio. estimated AK cases in Germany. In 2011 AK accounted for 8.3% of the 
hundred most frequently treated dermatological outpatient diagnoses. The propor-
tion of AK cases has risen almost continuously over the last 10 years. Estimated 
annual number of AK cases documented by dermatologists in Germany is about 
1.7 Mio. ConClusions: AK is a frequent condition in higher age groups and more 
prevalent in men; a relevant need for health care evident. Predictors and risk factors 
for AK are easy to identify in the population, which could also help to detect groups 
with special need for preventive measures.
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objeCtives: To evaluate the budget impact of introducing ranibizumab. Methods: 
Cumulative costs were assessed using an open cohort model with a 5-year time 
horizon and NHS perspective. The number of eligible patients was based on: the 
estimated prevalence of pathologic myopia (PM) in the population > 40 years old 
(1.2%); the incidence of choroidal neovascularization (CNV) in patients with PM 
(0.98%); the proportion of patients eligible for pharmacotherapy (81%) and bilateral 
disease prevalence (5.5%). Treatment and diagnosis rates were estimated at 80% and 
83–86% respectively. Treatment frequency was based on RADIANCE trial data. The 
model compared two scenarios. In the ‘with ranibizumab’ scenario, the proportion 
of eligible patients treated with ranibizumab was estimated as 7% at year 1, increas-
ing to 32% at year 5; the proportion receiving verteporfin photodynamic therapy 
